Clinical Trial Search

Primary: Percentage of Participants Who Experienced One or More Dose-limiting Toxicities (DLTs) — 0; 0; 13; 0 Percentage of Participants

Primary: Maximum Drug Concentration (Cmax) in Plasma Determined Directly From Individual Concentration-time Data — 20.0; 17.9; 18.4; 17.5 ng/mL

Primary: Endoscopic Score - Cryer Score — 4; 4 Cryer score

Primary: Number of Participants With One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration — 0; 0; 1; 0 number of…

Primary: Steady-state Area Under the Plasma Concentration Versus Time Curve From Time Zero to 12 Hours of Oseltamivir and Oseltamivir Carboxylate — 277; 194; 142; 4990 hour…

Primary: Number of Benevolent Rounds — 6.8; 6.8 number of rounds

Primary: Regional DRD2/3 Binding Percent Changes After Bariatric Surgery — -10.14; -9.39; -8.11; -8.76 percentage of binding potential change

Primary: Change in Test Scores on Knowledge of Course Content From Baseline to 30 Days — 39.3 units on a scale

Primary: Minimum Serum Concentration (Cmin) of TCZ at Steady State — 13.35; 12.71 Micrograms/milliliter (mcg/mL)

Primary: Maximum Observed Plasma Concentration (Cmax) of S-ibuprofen — 13268.7; 14967.2 nanogram (ng)/ millilitre (mL)

Primary: Number of Patients Evulated for Toxicity and Safety — 17; 17 participants

Primary: Area Under the Concentration-time Curve of BI 113608 in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point (AUC0-tz) — 494; 1840; 1320…

Primary: Number of Adverse Events — 61; 35; 52; 38 Number of AE reported

Primary: Number of Healthy and Asthmatic Participants With Events of Clinical Interest (ECI) (Part 1) — 1; 0; 0; 0 Participants

Primary: Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs) — 5; 3; 9; 5 participants